Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tuvusertib and ZEN-3694 in Recurrent Ovarian and Endometrial Cancer
NCT05950464Phase 1Recruiting
- Sponsor
- National Cancer Institute
- Start
- Dec 2023
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1 trial of tuvusertib and ZEN3694, sponsored by National Cancer Institute. Started Dec 2023; status: recruiting.
02
Drugs
tuvusertibZEN3694
Beyond the preview
Go deeper on NCT05950464.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05950464.